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Translational relevance 
The presence of a conspicuous local inflammatory reaction is associated with improved 
survival of patients with colorectal cancer independent of stage, whereas the presence of 
elevated systemic inflammatory responses, as measured by acute phase proteins, is associated 
with decreased survival. One potential candidate pathway linking these responses is the Janus 
kinase/ signal transduction and activator of transcriprition-3 (JAK/STAT3) pathway, with 
increasing evidence that this is a potential therapeutic target in cancer.  In the present study, 
increased expression and nuclear localisation of STAT3 was associated with aberrant local 
and systemic inflammatory responses in patients undergoing resection of stage I-III colorectal 
cancer, and was associated with poorer survival. In addition to suggesting a role for 
JAK/STAT3 inhibitors in restoring host anti-tumour immune responses, the results of the 
present study further support the rationale for stratifying patients by host inflammatory 
responses in future trials of such agents. 
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Abstract 
Purpose 
In patients with colorectal cancer (CRC), a high-density local inflammatory infiltrate 
response is associated with improved survival, whereas elevated systemic inflammatory 
responses are associated with poor survival. One potential unifying mechanism is the IL-
6/JAK/STAT3 pathway. The present study examines the relationship between tumour total 
STAT3 and phosphorylated STAT3Tyr705 (pSTAT3) expression, host inflammatory responses 
and survival in patients undergoing resection of stage I-III CRC. 
Experimental Design 
Immunohistochemical assessment of STAT3/pSTAT3 expression was performed using a 
tissue microarray and tumour cell expression divided into tertiles using the weighted 
histoscore. The relationship between STAT3/pSTAT3 expression and local inflammatory 
(CD3+, CD8+, CD45R0+, FOXP3+ T-cell density and Klintrup-Mäkinen grade) and systemic 
inflammatory responses and cancer-specific survival were examined.  
Results 
196 patients were included in the analysis. Cytoplasmic and nuclear STAT3 expression 
strongly correlated (r=0.363, P<0.001); nuclear STAT3 and pSTAT3 expression weakly 
correlated (r=0.130, P=0.068).  Cytoplasmic STAT3 was inversely associated with the 
density of CD3+ (P=0.012), CD8+ (P=0.003) and FOXP3+ T-lymphocytes (P=0.002) within 
the cancer cell nests and was associated with an elevated systemic inflammatory response as 
measured by modified Glasgow Prognostic Score (mGPS2: 19% vs. 4%, P=0.004). 
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The combination of nuclear STAT3/pSTAT3 stratified five-year survival from 81% to 62% 
(P=0.012), however was not associated with survival independent of venous invasion, tumour 
perforation or tumour budding.  
Conclusion 
In patients undergoing CRC resection, STAT3 expression was associated with adverse host 
inflammatory responses and reduced survival. Up-regulation of tumour STAT3 may be an 
important mechanism whereby the tumour deregulates local and systemic inflammatory 
responses. 
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INTRODUCTION 
Colorectal cancer is the second most common cause of cancer death in Europe. 
Despite improved outcomes over the past decades, survival still remains poor, with 5-year 
survival of around 50% across all disease stages (1).  Indeed, it is clear that the present TNM-
based staging of colorectal cancer is suboptimal, with a need to identify characteristics 
pertaining to both the tumour and the host which may not only guide prognosis, but also the 
need for existing and novel adjuvant therapies.  
One such characteristic is tumour-associated inflammation, which is now undisputed 
as impacting on both the development and progression of cancer (2).  In patients with 
colorectal cancer, for example, host local and systemic inflammatory responses are important 
determinants of disease progression, and their assessment is now accepted as holding 
independent prognostic value.  To date, over 100 studies have examined the role of the local 
inflammatory cell infiltrate in determining outcome in patients with colorectal cancer (3), 
with a consistent, stage-independent decrease in disease recurrence and increase in survival 
observed in association with the presence of a conspicuous inflammatory cell infiltrate (3, 4). 
In contrast, an elevated systemic inflammatory response is associated with increased 
risk of recurrence and reduced survival across a number of cancers including colorectal 
cancer (5).  Up-regulation of the systemic inflammatory response, as characterised by 
dysregulation of circulating pro-inflammatory cytokines, acute phase proteins such as C-
reactive protein (CRP) and albumin (6), and myeloid cells (7, 8), propagates a systemic 
environment which favours tumour growth and metastasis (9).  Furthermore, routine 
assessment of the systemic inflammatory response utilising routinely available biomarkers, 
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such as acute phase proteins and components of the differential white cell count, informs 
prognosis complimentary to current TNM-based staging (8, 10). 
One potential mechanism linking the local and systemic inflammatory responses is 
activation of the Janus-activated kinase/ signal transduction and activator of transcription-3 
(JAK/STAT3) pathway by interleukin-6 (IL-6).  Circulating IL-6 is commonly elevated in a 
number of cancers, including colorectal cancer (11-13), and is the predominant stimulus for 
the hepatic synthesis of acute phase proteins, including CRP (6).  Cancer-associated 
fibroblasts and inflammatory cells contribute to high levels of IL-6 within the tumour 
microenvironment (14, 15), with subsequent tumour cell activation of the soluble IL-6 
receptor/ glycoprotein 130 complex (16).  Interleukin-6 trans-signalling regulates JAK 
activity within the tumour cell to promote phosphorylation of the tyrosine 705 residue of 
STAT3.  Phosphorylated STAT3 (pSTAT3) translocates to the nucleus where it is a key 
transcription factor for numerous Th2-type cytokines, including IL-6 (12, 14), which promote 
a pro-tumour, immunosuppressive environment and attenuate host anti-tumour immune 
responses (15, 17).  Indeed, given its role in not only de-regulation of the host anti-tumour 
immune response, but also in orchestrating numerous pro-oncogenic processes (15, 18, 19), it 
is not surprising that STAT3 expression and activation has previously been associated with 
reduced survival in a number of gastrointestinal cancers, including colorectal cancer (20).  
We hypothesise that the host systemic and local inflammatory responses in patients 
with colorectal cancer may be linked by STAT3.  As such, the aim of the present study was to 
examine the relationship between tumour cell STAT3 expression, host local and systemic 
inflammatory responses and survival in a cohort of patients undergoing potentially curative, 
elective resection of stage I-III colorectal cancer. 
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MATERIALS AND METHODS 
Patients who between 1997 and 2007 had undergone elective, potentially curative 
resection for stage I-III colorectal cancer in a single surgical unit in Glasgow Royal 
Infirmary, and who were included in a previously constructed tissue microarray (TMA) were 
included.  Resection was considered curative on the basis of pre-operative computed 
tomography and intra-operative findings.  Patients were excluded on the following criteria: 
emergency resection, resection with palliative intent, resection for IBD-associated colorectal 
cancer, known familial cancer syndrome, neoadjuvant therapy, underlying inflammatory 
condition, or death within 30 days of surgery.  Local ethical approval was obtained from the 
West of Scotland Research Ethics Committee and tissue for analysis of STAT3 expression 
was obtained from the National Health Service Greater Glasgow & Clyde Tissue 
Biorepository 
Patient demographics were collected prospectively.  Tumours were staged using 
AJCC/UICC-TNM 5th edition, consistent with current Royal College of Pathologist 
guidelines (21).  The presence of venous invasion was assessed routinely using elastica 
staining.  Following surgery, patients were discussed at local colorectal cancer 
multidisciplinary meetings, where patients with stage III or high-risk stage II disease were 
considered for 5-fluorouracil-based chemotherapy according to treatment protocols at the 
time.  Patients were followed up for a minimum of five years according to local guidelines at 
the time.  Date and cause of death were crosschecked with the cancer registration system and 
the Registrar General (Scotland).  Death records were complete until 31st March 2014 that 
served as the censor date.  Cancer-specific survival was measured from date of surgery until 
date of death from colorectal cancer. 
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Serum CRP, albumin and differential white cell count were measured within 30 days 
prior to surgery and recorded prospectively. Pre-operative systemic inflammatory responses 
were defined using the modified Glasgow Prognostic Score (mGPS), the neutrophil: 
lymphocyte ratio (NLR) and the neutrophil: platelet score (NPS). The mGPS was calculated 
as previously described (10); patients with CRP ≤10mg/L were allocated a score of 0, 
patients with CRP >10mg/L and albumin ≥35g/L were allocated a score of 1, and patients 
with CRP >10mg/L and albumin <35g/L were allocated a score of 2. On the basis of 
previously published thresholds, NLR>5 was considered elevated (7).  The NPS was 
calculated as previously described (22); patients with a platelet count<400x109/L and 
neutrophil count<7. 5x109/L were allocated a score of 0, either a neutrophil count>7.5x109/L 
or platelet count>400x109/L a score of 1, and those with both an elevated neutrophil and 
platelet count a score of 2. 
 Assessment of tumour microenvironment 
The tumour-associated stroma, the generalised local inflammatory cell infiltrate and 
tumour budding have previously been characterised in this cohort using full haematoxylin & 
eosin (H&E)-stained sections of the deepest point of invasion according to previously 
published methodology (23-26).  The tumour-associated stroma was assessed using tumour 
stroma percentage (TSP) and graded as either low (≤50%) or high (>50%) (25).  The local 
inflammatory cell infiltrate was assessed using the Klintrup-Mäkinen (KM) grade and graded 
as either low-grade (no increase or mild/patchy increase in inflammatory cells at invasive 
margin) or high-grade (prominent band-like inflammatory reaction or florid cup-like 
inflammatory reaction at invasive margin with destruction of cancer cell islands) (27).  
Tumour budding was examined using the 10-high powered field method as previously 
described Tumour budding was examined using the 10-high powered field method as 
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previously described (26).  Budding was considered high grade if greater than 20 buds 
(tumour cells with less than five nuclei or single tumour cells) were identified per 10-high 
powered fields. 
Immunohistochemistry for CD3+ (mature), CD8+ (cytotoxic), CD45R0+ (memory) and 
FOXP3+ (regulatory) T-lymphocytes was performed using formalin fixed paraffin embedded 
full sections of the deepest point of invasion as previously described (27).  Cellular epitopes 
were identified using the following antibodies: CD3 (Vector Labs, code VP-RM01, 1:100 
dilution), CD8 (DakoCytomation, code M7103, 1:100 dilution), CD45R0 (DakoCytomation, 
code M0742, 1:150 dilution) and FOXP3 (Abcam, code 20034, 1:200 dilution).  T-
lymphocyte density at the invasive margin or within the cancer cell nests was semi-
quantitatively graded using a four-point scale (absent/ low/ moderate/ high).  For the purposes 
of statistical analysis, density was subsequently graded as low (absent/ low) or high 
(moderate/ high).  Investigators blinded to clinicopathological data and outcomes performed 
all assessments, with independent scoring of 10% of cases by two investigators to ensure 
consistency. 
Assessment of STAT3 expression 
Immunohistochemical assessment of tumour cell STAT3 activity was performed 
using a previously constructed colorectal cancer TMA consisting of four 0.6mm cores per 
patient (28).  The TMA was constructed from formalin fixed paraffin embedded tissue blocks 
corresponding to the full sections utilised for assessment of the tumour microenvironment.  In 
addition to activation of STAT3 by phosphorylation of the tyrosine 705 residue by IL-6/JAK 
activation, activation may also occur through phosphorylation of the serine 727 residue in 
response to MAPK activation (29).  As the present study hypothesised an association between 
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the systemic and local inflammatory response via IL-6/JAK/STAT3 activation, only total 
STAT3 expression and phosphorylated STAT3Tyr705 (pSTAT3) expression was measured.  
Sections were dewaxed in xylene before being rehydrated using graded alcohols.  Antigen 
retrieval was performed using a citrate buffer at 96oC for 20 minutes for STAT3, and using a 
Tris-EDTA buffer at high pressure in a microwave for 5 minutes for pSTAT3.  Endogenous 
peroxidase activity was blocked using 3% hydrogen peroxide for 10 minutes before rinsing in 
water.  Casein and 5% horse serum in TBS were applied for 20 minutes at room temperature 
as a blocking agent for STAT3 and pSTAT3 respectively.  Sections were then incubated 
overnight at 4oC with the primary antibody (STAT3: product code 9132, Cell Signaling 
Technologies; pSTAT3: product code 9131, Cell Signaling Technologies) at a concentration 
of 1:100 and 1:50 for STAT3 and pSTAT3 respectively before washing in TBS for ten 
minutes.  Envision (Dako) was then added to the sections for 30 minutes at room temperature 
before washing in TBS for ten minutes.  DAB substrate was added for five minutes until 
colour developed before washing in running water for ten minutes.  Slides were 
counterstained in haematoxylin for 60 seconds and blued with Scotts’ tap water before 
dehydration through graded alcohols.  Cover slips were applied using distrene, plasticizer, 
xylene.  
Sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, UK) at x20 magnification and visualization was carried out using Slidepath 
Digital Image Hub (Slidepath, Leica Biosystems, Milton Keynes, UK).  Assessment of 
STAT3 and pSTAT3 expression within the cancer cell cytoplasm and nucleus was performed 
at x20 magnification by a single examiner (J.H.P) blinded to clinical using the weighted 
histoscore (30).  To ensure reproducibility of scoring, 15% of tumours were co-scored by a 
second investigator (J.C.); the intraclass correlation coefficient was 0.826 and 0.837 
respectively.  For the purposes of the present study, cytoplasmic STAT3 expression was 
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considered representative of total STAT3 expression whereas nuclear STAT3 and pSTAT3 
expression were considered representative of STAT3 transcriptional activity. 
 Assessment of mismatch repair status 
 Mismatch repair (MMR) protein deficiency was determined using the TMA utilised 
for STAT3 assessment.  Sections were stained for MLH1, MSH6, MSH2 and PMS2 (product 
codes: M3640, M3646, M3639 and M3647, respectively; Dako UK Ltd, Cambridgeshire, 
UK) as described previously (31).  Mismatch repair status was determined according to UK 
NEQAS guidelines (32), using appendix and normal colon as positive controls and intra-
tumoural lymphocytes as internal positive controls.  Tumours were considered MMR 
competent if tumour cell nuclear expression was positive with positive immune cell 
expression, and MMR deficient if tumour nuclear expression was absent with normal 
immune cell expression. 
Statistical analysis 
For the purpose of statistical analysis, patients were divided into tertiles (low/ 
moderate/ high) on the basis of cytoplasmic and nuclear STAT3 and pSTAT3 expression as 
measured by h-score.  The relationship between clinicopathological characteristics and 
cytoplasmic and nuclear STAT3 expression was examined using the Chi-square test for linear 
trend. The relationship between STAT3 expression and five-year cancer-specific survival was 
examined using Kaplan-Meier log-rank analysis and displayed as percentage surviving 
(standard error).  The relationship between STAT3 expression, clinicopathological 
characteristics and cancer-specific survival was examined using Cox proportional hazards 
regression; variables with a P≤0.1 on univariate analysis were entered into a multivariate 
model using a backwards conditional model to calculate hazard ratios (HR) and 95% 
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confidence intervals (CI).  Given the number of comparisons performed, a P-value ≤0.01 was 
considered statistically significant for Chi-square analysis, with a P-value ≤0.05 considered 
statistically significant for survival analysis. All analyses were performed using SPSS version 
22.0 (IBM SPSS).  
 13 
RESULTS 
A total of 196 patients who underwent elective, potentially curative resection of stage 
I-III colorectal cancer were included.  Clinicopathological characteristics are displayed in 
Table 1.  Almost two thirds of patients were older than 65 at time of surgery and 52% were 
male.  Pathological assessment confirmed Stage I disease in 16 patients (8%), stage II disease 
in 94 patients (48%) and stage III disease in 86 patients (44%).  Fifty-four patients (28%) 
received adjuvant therapy; 1 patient with stage I disease, 14 patients with stage II disease and 
39 patients with stage III disease received adjuvant therapy.  Mismatch repair deficiency was 
identified in 27 patients (14%).   
Expression of STAT3 was observed in both the cytoplasm and nucleus, whereas 
pSTAT3 expression was only observed in the nucleus.  The h-score range for cytoplasmic 
and nuclear STAT3 expression ranged from 0-168 and from 0-130 respectively.  Nuclear 
pSTAT3 h-score for the cohort ranged from 5-205.  Cytoplasmic expression of STAT3 was 
associated with nuclear expression of STAT3 (Spearman’s r=0.363, P<0.001) but not 
pSTAT3 (r=0.111, P=0.121).  Nuclear STAT3 expression was not significantly associated 
with nuclear pSTAT3 expression (r=0.130, P=0.068).  Normal, non-cancer epithelium 
expression of STAT3 was available for 10 patients.  Although this precluded meaningful 
statistical analysis, it was of interest that 7 patients showed similar or higher expression of 
cytoplasmic STAT3, nuclear STAT3 and nuclear pSTAT3 in normal tissue compared to 
cancer tissue.  The remaining three patients showed heterogeneous expression of each of the 
studied markers. 
 The relationship between STAT3 and pSTAT3 expression tertiles and 
clinicopathological characteristics is displayed in Table 1.  Cytoplasmic expression of STAT3 
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was not associated with any clinicopathological characteristics.  Although failing to reach 
statistical significance (P≤0.01), nuclear STAT3 expression showed an inverse association 
with use of adjuvant chemotherapy (P=0.038), whereas pSTAT3 expression was associated 
with younger age were younger (P=0.026) and an increased prevalence of lymph node 
positive disease (low pSTAT3 expression – 35% vs. high pSTAT3 expression – 52%, 
P=0.039). 
The relationship between STAT3 and pSTAT3 expression and components of the 
tumour microenvironment is displayed in Table 2.  Cytoplasmic STAT3 expression was 
inversely associated with the cancer cell nest density of CD8+ and FOXP3+ (both P<0.01) T-
lymphocytes and showed a trend towards a similar relationship with CD3+ density (P=0.012) 
but was not associated with TSP, tumour budding or the local inflammatory cell density at the 
invasive margin as measured by Klintrup-Mäkinen grade or T-lymphocyte density.  Nuclear 
expression of STAT3 showed no statistically significant association with characteristics of 
the tumour microenvironment, however a lower density of CD8+ (P=0.039) and CD3+ 
(P=0.055) T-lymphocytes was identified in patients with nuclear STAT3 expression.  There 
were no statistically significant associations between nuclear pSTAT3 expression and tumour 
microenvironment characteristics; patients with high nuclear pSTAT3 expression however 
were observed to have a lower density of CD45R0+ T-lymphocytes (P=0.037) and more 
frequent high-grade tumour budding (P=0.022). 
When analysis was restricted to patients with MMR competent colorectal cancer 
(Supplementary Table 1), the observed relationship between cytoplasmic STAT3 and cancer 
cell nest density of CD3+ (P=0.061) CD8+ (P<0.05) and FOXP3+ (P<0.01) T-lymphocytes 
remained.  Nuclear STAT3 was no longer associated with CD8+ density within cancer cell 
nests but was associated with CD3+ density within the invasive margin (P<0.05).  Nuclear 
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pSTAT3 expression again showed a non-significant trend towards low cancer cell nest 
density of CD45R0+ T-lymphocytes.  Although the small number of patients limited 
statistical power, when analysis was restricted to patients with MMR deficient colorectal 
cancer, the relationship between cytoplasmic STAT3 expression and cancer cell nest density 
of CD3+ (P<0.05) and CD8+ (P<0.01) T-cells, and nuclear STAT3 expression and cancer cell 
nest density of CD8+ T-cells (P<0.05) remained.  Nuclear pSTAT3 expression, however, was 
not associated with T-lymphocyte density of patients with MMR deficient colorectal cancer. 
The relationship between STAT3 and pSTAT3 expression and systemic inflammatory 
responses is displayed in Table 3.  Cytoplasmic STAT3 expression was associated with the 
systemic inflammatory response as measured by mGPS; this was predominantly due to an 
increase in the number of patients with mGPS=2 (high expression – 19% vs. low expression 
4%, P=0.004).  Neither cytoplasmic nor nuclear STAT3 expression were associated with the 
systemic inflammatory response as measured by circulating platelets or components of the 
differential white cell count.  Nuclear pSTAT3 expression was not associated with any 
measures of the systemic inflammatory response. 
The median follow-up of survivors was 143 months (range 101-204) with 57 cancer-
associated deaths and 64 non-cancer deaths.  For the purposes of survival analysis, low and 
moderate expression of each marker was combined to form one group (low expression).  The 
relationship between cytoplasmic STAT3, nuclear STAT3 and nuclear pSTAT3 and cancer-
specific survival is displayed in Figure 1 and in Table 4.  High nuclear STAT3 expression 
was associated with poorer cancer-specific survival (P<0.05).  High expression of both 
cytoplasmic STAT3 expression and nuclear pSTAT3 expression showed a non-significant 
trend towards poorer survival (P=0.068 and P=0.116 respectively). 
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To examine the relationship between expression and activation of STAT3 and 
survival, the cumulative prognostic value of cytoplasmic STAT3, nuclear STAT3 and nuclear 
pSTAT3 was examined with respect to five-year cancer-specific survival (Table 4).  Three 
models were examined: model 1 (cytoplasmic STAT3/ nuclear STAT3) stratified survival 
from 81% (low expression of both) to 63% (high expression of both) (P=0.022), model 2 
(cytoplasmic STAT3/ nuclear pSTAT3) stratified survival from 81% to 54% (P=0.018), and 
model 3 (nuclear STAT3/ nuclear pSTAT3) stratified survival from 81% to 62% (P=0.012).  
When the three models were entered into a multivariate model using a backwards conditional 
method, only model 3 (nuclear STAT3/ nuclear pSTAT3) remained independently associated 
with cancer-specific survival (HR 1.63, 95%CI 1.14-2.34 P=0.008, Figure 1). 
The relationship between this prognostic model and cancer-specific survival was 
examined on multivariate analysis.  As the prognostic value of the Klintrup-Mäkinen grade 
has previously been shown to be similar to assessment of individual T-lymphocyte subsets 
(24), only Klintrup-Mäkinen grade was entered into the multivariable model.  On multivariate 
survival analysis (Table 5), combined nuclear STAT3/ pSTAT3 expression was not 
associated with cancer-specific survival (P=0.220), whereas venous invasion (HR 2.89, 
P=0.001), tumour perforation (HR 8.30, P<0.01), NPS (HR 1.69, P<0.05) and tumour 
budding (HR 4.12 P<0.00) were all independently associated with survival.  Low Klintrup-
Mäkinen grade (HR 2.14, P=0.060) and elevated mGPS (HR 1.52, P=0.060) showed a trend 
towards poorer survival, however failed to reach statistical significance.   
The prognostic value of combined nuclear STAT3/pSTAT3 expression as stratified by 
T stage and N stage was examined (Supplementary Figure 1).  Nuclear STAT3/pSTAT3 
expression was associated with reduced survival of patients with T1-2 colorectal cancer 
(P<0.001) but was not associated with survival of patients with T3-4 colorectal cancer 
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(P=0.192).  Furthermore, nuclear STAT3/pSTAT3 expression stratified survival of patients 
with lymph node positive (P=0.001) but not lymph node negative disease (P=0.516). 
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DISCUSSION 
In the present study of patients undergoing elective, potentially curative colorectal 
cancer resection, STAT3 was not associated with clinicopathological characteristics of the 
tumour but was associated with adverse host inflammatory responses.  In particular, increased 
tumour cell STAT3 expression was associated with down-regulation of the local 
inflammatory cell infiltrate.   
Although in keeping with previous clinical studies of colorectal and pancreatic 
adenocarcinoma (33, 34), the present study is to our knowledge the first to examine the 
relationship between tumour STAT3 expression and the density of the local adaptive immune 
infiltrate as evidenced by T-lymphocytes in the clinical context of patients with 
gastrointestinal cancer.  Whereas previous studies found a decrease in the density of the 
generalised inflammatory cell infiltrate or tumour-infiltrating lymphocytes using H&E-based 
assessments (33, 34), the present study utilised immunohistochemistry and found a decrease 
in the density of tumour-associated T-lymphocyte populations.  Indeed, this would suggest a 
direct effect of STAT3 activation on adaptive, T-lymphocyte-mediated anti-tumour 
immunity.  Furthermore, the relationship between STAT3 expression and the local 
inflammatory cell infiltrate would appear to be independent of MMR status. 
Although assessment of cytoplasmic STAT3 expression was significantly associated 
with the density of T-lymphocytes, it was of interest that the K-M grade, an assessment of the 
generalised inflammatory cell infiltrate, did not differ with STAT3 expression.  This may 
reflect the ability of STAT3 to simultaneously suppress anti-tumour immune responses whilst 
promoting pro-tumour immunity (17, 35).  Whereas anti-tumour, adaptive, Th1-polarised 
immune responses are down-regulated (36, 37), STAT3-dependent transcription and release 
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of Th2-type cytokines favours recruitment of tumour-promoting tumour-associated 
macrophages and myeloid-derived cells (17).  Furthermore, STAT3 activation may 
additionally favour the differentiation of naïve T-lymphocytes into tumour-promoting 
lymphocytic subsets (17).  Consistent with such a hypothesis, Morikawa and colleagues 
found that although intratumoural lymphocyte density decreased, the density of the 
peritumoural inflammatory cell infiltrate increased with increasing STAT3 activity in a 
cohort of patients with stage I-IV colorectal cancer (33).  Furthermore, it has been shown in 
some tumours, such as ependymomas, that STAT3 immunosuppression is mediated by up-
regulation of myeloid-derived cell activity, with a subsequent deleterious effect on T-
lymphocytic, anti-tumour activity (38).  As such, future studies of STAT3 activation in 
patients with gastrointestinal cancers should also consider the nature and density of local 
innate immune responses. 
Of interest, pSTAT3 expression was associated with high-grade tumour budding.  The 
presence of tumour buds is a phenotypic characteristic of epithelial-mesenchymal 
transitioning (EMT), a vital step in tumour cell dissemination which requires immune cell 
evasion (39).  The present results may suggest that STAT3 activation is one mechanism by 
which tumour buds evade host anti-tumour immune responses.  However, it is also 
recognised that STAT3 activation promotes tumour cell stemness and is an upstream 
activator of EMT (40, 41), which may explain the present associations. 
Although failing to reach statistical significance, the density of tumour-associated 
stroma, as measured by TSP, appeared to be associated with pSTAT3 expression.  Given that 
an increase in TSP primarily reflects an increased population of cancer-associated fibroblasts 
within the tumour microenvironment, this would further support the importance of IL-6 
secretion by fibroblasts in the activation of the JAK/STAT3 pathway in tumour cells (14, 15).  
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Indeed, the present results suggest that the JAK/STAT3 pathway may be an important 
mechanism by which the tumour influences the composition of the tumour microenvironment 
and deregulates host anti-tumour immune responses. 
The present study found that increased tumour STAT3 expression was associated with 
elevated systemic inflammatory responses as measured using the mGPS, a cumulative score 
based on serum CRP and albumin concentrations.  Such routinely measured biomarkers of 
the systemic inflammatory response represent only “the tip of a far larger iceberg” of cancer-
associated systemic inflammation, whereby circulating cytokines, growth factors and 
myeloid-derived cells promote cancer progression and dissemination (9).  One such cytokine, 
IL-6, is commonly elevated in colorectal cancer (11, 13), and is the main determinant of 
hepatic synthesis of CRP and responsible for the acute phase reduction in hepatic albumin 
synthesis (6).  Given the importance of IL-6 as both an activator of the JAK/STAT3 pathway 
and as an end product of its activation, the present results are perhaps not surprising, and 
suggest that STAT3 activation may play a role in the systemic inflammatory response in 
colorectal cancer. 
However, although STAT3 expression was associated with an elevated mGPS, it was 
not associated with components of the differential white cell count.  This is in keeping with 
previous work from Guthrie and colleagues, whereby serum IL-6 concentration correlated 
strongly with the mGPS but not the NLR in patients with colorectal cancer (13).  However, 
other groups have found contradictory results, with a positive association between serum IL-6 
concentrations and the NLR in patients with colorectal cancer.  This disparity may be 
explained by differences in the groups studied; whereas the patients in the present study and 
that of Guthrie and colleagues were undergoing potentially curative resection of stage I-III 
colorectal cancer, the groups studied by Kantola and Chen included patients with stage I-IV 
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colorectal cancer at varying stages of treatment.  Taken together, it would appear that, at least 
in patients with non-metastatic colorectal cancer, the effects of the IL-6/JAK/STAT3 pathway 
on the cancer-associated systemic inflammatory response may not be entirely modulated by 
an effect on circulating innate and adaptive immune cells. 
Of interest, only total cytoplasmic STAT3 expression was associated with the 
systemic inflammatory response as measured by mGPS.  The reason for this is not clear, 
however may represent the dynamic nature of JAK/STAT3 activation and translocation.  
Although activation of the IL-6 receptor leads to rapid accumulation of STAT3, mechanistic 
studies have shown that less than 30% of total cytoplasmic STAT3 translocates to the nucleus 
on cytokine stimulation (42).  Furthermore, STAT3 also exhibits transcription-independent 
activity within the cytoplasm without nuclear translocation (42, 43).  Another plausible 
hypothesis is that rather than being directly causative, the presently observed associations 
between the mGPS and tumour cell STAT3 expression may represent separate down-stream 
events of a common precursor, such as elevated systemic IL-6 concentrations.  Finally, given 
the lack of a consistent relationship across different measures of the systemic inflammatory 
response, the present results may simply represent a Type-I statistical error.  Indeed, rather 
than the tumour itself, other end organs, such as liver or skeletal muscle, may be the 
predominant drivers of the systemic inflammatory response in such patients (44).  As such, 
the present observations should be regarded as hypothesis-generating, and remain to be 
further investigated by mechanistic and clinical studies. 
Consistent with previous reports in patients with gastrointestinal cancers (20), the 
present study found that increased tumour cell STAT3 expression and activity was associated 
with reduced survival.  The pleiotropic nature of STAT3 activation is reflected in the fact that 
combined assessment of total nuclear STAT3 and pSTAT3 held greater prognostic value than 
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either measure alone.  Whereas the present study investigated IL-6/JAK-mediated activation 
of STAT3 by phosphorylation of tyrosine residue 705, mitogen-activated protein kinase-
dependent activation results in phosphorylation of the serine 727 residue, with differing 
results on transcriptional activity (29).  Furthermore, STAT3 may also undergo nuclear 
import without phosphorylation (45).  In addition to its role in mediating host immune 
responses, STAT3 activation plays an integral role in many key tumour cell pathways, 
including proliferation, epithelial-mesenchymal transitioning and promotion of cancer cell 
stemness (40).  Indeed, the heterogeneity of upstream activation of STAT3 is reflected in the 
present results, whereby 74 patients showed discordant expression of nuclear STAT3 and 
pSTAT3.  As such, further investigation of these other upstream pathways, and their 
relationship to the present results is required.  Furthermore, rather than targeting upstream 
activation of STAT3, future therapeutic strategies may benefit from targeting STAT3 itself 
and its subsequent activation.  
Nuclear STAT3/pSTAT3 expression showed differential prognostic value according 
to T stage and N stage.  Although potentially reflecting the limited statistical power of the 
present study for subgroup analysis, the present results could suggest that STAT3 activation 
and expression may have a differential effect dependent on disease stage and invasiveness.  
In addition, assessment of the local and systemic environment held greater prognostic value 
than nuclear STAT3/pSTAT3 expression.  Rather than being defined by one mechanism such 
as the JAK/STAT3 pathway, characteristics within the tumour microenvironment and the 
systemic inflammatory response are likely to be multifactorial in origin.  Therefore, it might 
be anticipated that such phenotypic characteristics would be of greater prognostic value than 
a single signal transduction pathway.  Indeed, it would be of considerable interest to examine 
and compare other signal transduction pathways associated with inflammation, such as the 
NF-κB pathway (46, 47), in future studies.  
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The present study provides further clinical evidence of the role of the IL-
6/JAK/STAT3 pathway in the amelioration of host anti-tumour immune responses, and raises 
two interesting points that remain to be investigated.  Firstly, it would suggest a role for 
inhibitors of the IL-6/JAK/STAT3 pathway in restoring anti-tumour immune responses in 
patients with colorectal cancer (48, 49).  Secondly, it would support the hypothesis that 
routine markers of the systemic inflammatory response, and in particular the mGPS, may aid 
in the identification and selection of patients likely to benefit from such targeted therapies 
(50).  In keeping with such a scheme, one recent clinical trial of a JAK inhibitor in patients 
with metastatic pancreatic cancer found an increase in overall survival only in those patients 
with an elevated CRP or mGPS (51).  Therefore, it is clear that markers of the host 
inflammatory response should be incorporated into future studies of agents targeting the IL-
6/JAK/STAT3 pathway in cancer.  
Given the increasing appreciation of distinct molecular subtypes of colorectal cancer 
(52), the results of the present study are perhaps limited by the lack of molecular 
characterisation of the tumours studied.  Although not associated with MMR status in the 
present cohort, the relationship between STAT3 and other characteristics, such as KRAS and 
BRAF status, would be of interest.  However, a previous comprehensive study by Morikawa 
and colleagues found no association between STAT3, a number of molecular characteristics 
and survival in a cohort of over 700 patients (33).  Furthermore, it has also been suggested 
that STAT3 may have a role in not only induction of KRAS mutated tumours (53), but also in 
conferring chemoresistance in patients with KRAS wild-type tumours (54).  Indeed, this 
would suggest that STAT3 is independent of such characteristics.  A further limitation is the 
relatively small sample size, precluding meaningful subgroup analysis.  Analysis was 
restricted to a previously constructed TMA, and only patients who had complete staining for 
both STAT3 and pSTAT3 were included.  However, post-hoc power calculation shows that 
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the present study has adequate power to examine the relationship between STAT3 and the 
local and systemic environment.  For example, post-hoc analysis suggests that the present 
study holds 84% power to determine a difference in cancer cell nest CD8+ T-lymphocyte 
density between those with low and high cytoplasmic STAT3 expression. 
In conclusion, the results of the present study suggest a relationship between tumour 
cell STAT3 expression and the host inflammatory response, and may be one potential 
mechanism whereby the tumour promotes a local and systemic environment amenable to 
tumour growth and dissemination.  Further studies are required to confirm such a 
relationship, and whether therapeutic targeting of the IL-6/JAK/STAT3 may be utilised in the 
treatment of patients with colorectal cancer and elevated systemic inflammatory responses. 
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Table 1 The relationship between tumour cell STAT3 and pSTAT3 expression and clinicopathological characteristics of patients undergoing elective, 
potentially curative resection of stage I-III colorectal cancer 
 
  
   Cytoplasmic STAT3 h-score Nuclear STAT3 h-score Nuclear pSTAT3 h-score 
 All 
n-196 (%) 
Low 
(0-20)  
n=76 (%) 
Mod 
(21-65)  
n=56 (%) 
High 
(66-168) 
n=64 (%) 
P Low 
(0-15) 
n=75 (%) 
Mod 
(16-30) 
n=66 (%) 
High 
(30-130) 
n=55 (%) 
P Low 
(5-80) 
n= 72 (%) 
Mod 
(81-105) 
n=61 (%) 
High 
(106-205) 
n=63 (%) 
P 
Host characteristics               
Age  
<65 
65-74 
>75 
 
72 (37) 
61 (31) 
63 (32) 
 
23 (30) 
29 (38) 
24 (32) 
 
22 (39) 
18 (32) 
16 (29) 
 
27 (42) 
14 (22) 
23 (36) 
0.571  
29 (39) 
25 (33) 
21 (28) 
 
25 (37) 
22 (33) 
10 (29) 
 
18 (33) 
14 (26) 
23 (41) 
0.199  
19 (26) 
23 (32) 
30 (42) 
 
26 (43) 
19 (31) 
16 (26) 
 
27 (43) 
19 (30) 
17 (27) 
0.026 
Sex  
Female 
Male 
 
94 (48) 
102 (52) 
 
40 (53) 
36 (47) 
 
21 (37) 
35 (63) 
 
33 (52) 
31 (48) 
0.833  
35 (47) 
40 (53) 
 
31 (47) 
35 (53) 
 
28 (51) 
27 (49) 
0.647  
38 (53) 
34 (47) 
 
23 (38) 
38 (62) 
 
33 (52) 
30 (48) 
0.906 
Adjuvant therapy  
No 
Yes  
 
142 (72) 
54 (28) 
 
55 (72) 
21 (28) 
 
44 (79) 
12 (21) 
 
43 (67) 
21 (33) 
0.532  
48 (64) 
27 (36) 
 
50 (76) 
16 (24) 
 
44 (80) 
11 (20) 
0.038  
56 (78) 
16 (22) 
 
41 (67) 
20 (33) 
 
45 (71) 
18 (29) 
0.389 
Tumour characteristics               
Tumour location  
Colon 
Rectum 
 
130 (66) 
66 (34) 
 
48 (63) 
28 (37) 
 
37 (66) 
19 (34) 
 
45 (70) 
19 (30) 
0.375  
47 (63) 
28 (37) 
 
43 (65) 
23 (35) 
 
40 (73) 
15 (27) 
0.242  
49 (68) 
23 (32) 
 
37 (61) 
24 (39) 
 
44 (70) 
19 (30) 
0.860 
T stage   
1-2 
3 
4 
 
25 (13) 
121 (61) 
50 (26) 
 
10 (13) 
49 (65) 
17 (22) 
 
9 (16) 
34 (61) 
13 (23) 
 
6 (9) 
38 (59) 
20 (31) 
0.288  
10 (13) 
46 (61) 
19 (25) 
 
10 (15) 
41 (62) 
15 (23) 
 
5 (9) 
34 (62) 
16 (29) 
0.480  
10 (14) 
43 (60) 
19 (26) 
 
8 (13) 
39 (64) 
14 (23) 
 
7 (11) 
39 (62) 
17 (27) 
0.694 
N stage  
0 
1 
2 
 
110 (56) 
68 (35) 
18 (9) 
 
47 (61) 
24 (32) 
5 (7) 
 
30 (53) 
20 (36) 
6 (11) 
 
33 (51) 
24 (38) 
7 (11) 
0.183 
 
 
34 (45) 
34 (45) 
7 (10) 
 
46 (70) 
16 (24) 
4 (6) 
 
30 (54) 
18 (33) 
7 (13) 
0.470  
47 (65) 
21 (29) 
4 (6) 
 
33 (54) 
21 (34) 
7 (12) 
 
30 (48) 
26 (41) 
7 (11) 
0.039 
TNM stage  
I 
II 
III 
 
16 (8) 
94 (48) 
86 (44) 
 
6 (8) 
41 (54) 
29 (38) 
 
7 (13) 
23 (41) 
26 (46) 
 
3 (5) 
30 (47) 
31 (48) 
0.211  
6 (8) 
28 (37) 
41 (55) 
 
8 (12) 
38 (58) 
20 (30) 
 
2 (4) 
28 (50) 
25 (46) 
0.494  
7 (10) 
40 (55) 
25 (35) 
 
5 (8) 
28 (46) 
28 (46) 
 
4 (6) 
26 (41) 
33 (52) 
0.051 
Tumour differentiation  
Mod/well 
Poor 
 
174 (89) 
22 (11) 
 
69 (91) 
7 (9) 
 
49 (87) 
7 (13) 
 
56 (87) 
8 (13) 
0.530  
63 (84) 
12 (16) 
 
60 (91) 
6 (9) 
 
51 (93) 
4 (7) 
0.108  
60 (83) 
12 (17) 
 
57 (93) 
4 (7) 
 
57 (91) 
6 (10) 
0.174 
Venous invasion  
No 
Yes 
 
129 (66) 
67 (34) 
 
51 (67) 
25 (33) 
 
39 (70) 
17 (30) 
 
39 (61) 
25 (39) 
0.465  
46 (61) 
29 (39) 
 
45 (68) 
21 (32) 
 
38 (69) 
17 (31) 
0.337  
51 (71) 
21 (29) 
 
39 (64) 
22 (36) 
 
39 (62) 
24 (38) 
0.271 
Margin involvement  
No 
Yes 
 
187 (95) 
9 (5) 
 
72 (95) 
4 (5) 
 
54 (96) 
2 (4) 
 
61 (95) 
3 (5) 
0.856  
70 (93) 
5 (7) 
 
65 (98) 
1 (2) 
 
52 (94) 
3 (6) 
0.649  
70 (97) 
2 (3) 
 
57 (93) 
4 (7) 
 
60 (95) 
3 (5) 
0.562 
Peritoneal involvement  
No 
Yes 
 
144 (3) 
52 (27) 
 
57 (75) 
19 (25) 
 
43 (77) 
13 (23) 
 
44 (69) 
20 (31) 
0.423  
55 (73) 
20 (27) 
 
50 (76) 
16 (24) 
 
39 (71) 
16 (29) 
0.794  
53 (74) 
19 (26) 
 
46 (75) 
15 (25) 
 
45 (71) 
18 (29) 
0.787 
Tumour perforation  
No 
Yes 
 
192 (98) 
4 (2) 
 
74 (97) 
2 (3) 
 
55 (98) 
1 (2) 
 
63 (98) 
1 (2) 
0.652  
73 (97) 
2 (3) 
 
66 (100) 
0 (0) 
 
53 (96) 
2 (4) 
0.799  
69 (96) 
3 (4) 
 
60 (98) 
1 (2) 
 
63 (100) 
0 (0) 
0.087 
Mismatch repair status  
Competent 
Deficient 
 
169 (86) 
27 (14) 
 
65 (85) 
11 (15) 
 
48 (86) 
8 (14) 
 
56 (87) 
8 (13) 
0.741  
62 (83) 
13 (17) 
 
59 (89) 
7 (11) 
 
48 (87) 
7 (13) 
0.406  
61 (85) 
11 (15) 
 
52 (85) 
9 (15) 
 
56 (89) 
7 (11) 
0.491 
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Table 2 The relationship between tumour cell STAT3 and pSTAT3 expression and tumour microenvironment of patients undergoing elective, potentially 
curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
  
  Cytoplasmic STAT3 h-score Nuclear STAT3 h-score Nuclear pSTAT3 h-score 
 Low 
(0-20)  
n=76 (%) 
Mod 
(21-65)  
n=56 (%) 
High 
(66-168) 
n=64 (%) 
P Low 
(0-15) 
n=75 (%) 
Mod 
(16-30) 
n=66 (%) 
High 
(30-130) 
n=55 (%) 
P Low 
(5-80) 
n= 72 (%) 
Mod 
(81-105) 
n=61 (%) 
High 
(106-205) 
n=63 (%) 
P 
Klintrup-Makinen grade  
Weak 
Strong 
 
28 (37) 
48 (63) 
 
20 (36) 
36 (64) 
 
17 (27) 
47 (73) 
0.208  
25 (33) 
50 (67) 
 
24 (36) 
42 (64) 
 
16 (29) 
30 (71) 
0.657  
26 (36) 
46 (64) 
 
19 (31) 
42 (69) 
 
20 (32) 
43 (68) 
0.582 
Tumour stroma 
percentage (195) 
 
Low 
High 
 
59 (78) 
17 (22) 
 
43 (78) 
12 (22) 
 
44 (69) 
20 (31) 
0.241  
56 (75) 
19 (25) 
 
51 (77) 
15 (23) 
 
39 (72) 
15 (28) 
0.794  
55 (78) 
16 (22) 
 
50 (82) 
11 (18) 
 
40 (64) 
22 (36) 
0.090 
Tumour budding (182)  
Low 
High 
 
45 (64) 
25 (36) 
 
40 (74) 
14 (26) 
 
38 (65) 
20 (35) 
0.834  
45 (63) 
26 (37) 
 
44 (76) 
14 (24) 
 
34 (64) 
19 (36) 
0.822 
 
 
49 (75) 
16 (25) 
 
41 (71) 
17 (29) 
 
33 (56) 
26 (44) 
0.022 
CD3+ margin density 
(184) 
 
Low 
High 
 
36 (49) 
37 (51) 
 
30 (60) 
20 (40) 
 
35 (57) 
26 (43) 
0.332  
37 (51) 
35 (49) 
 
28 (46) 
33 (54) 
 
36 (71) 
15 (29) 
0.055  
34 (54) 
29 (46) 
 
31 (52) 
28 (48) 
 
36 (58) 
26 (42) 
0.648 
CD3+ cancer cell nest 
density (192) 
 
Low 
High 
 
38 (51) 
37 (49) 
 
42 (79) 
11 (21) 
 
45 (70) 
19 (30) 
0.012  
47 (64) 
27 (37) 
 
38 (59) 
26 (41) 
 
40 (74) 
14 (26) 
0.262  
43 (62) 
26 (38) 
 
35 (58) 
25 (42) 
 
47 (75) 
16 (25) 
0.150 
CD8+ margin density 
(184) 
 
Low 
High 
 
41 (59) 
29 (41) 
 
34 (64) 
19 (36) 
 
33 (54) 
28 (46) 
0.630  
38 (53) 
34 (47) 
 
37 (61) 
25 (39) 
 
33 (65) 
18 (35) 
0.177  
38 (59) 
26 (41) 
 
33 (55) 
27 (45) 
 
37 (62) 
23 (38) 
0.806 
CD8+ cancer cell nest 
density (190) 
 
Low 
High 
 
41 (57) 
31 (43) 
 
45 (83) 
9 (17) 
 
51 (80) 
13 (20) 
0.003  
47 (63) 
27 (37) 
 
47 (76) 
15 (24) 
 
43 (80) 
11 (20) 
0.039  
50 (72) 
19 (28) 
 
41 (68) 
19 (32) 
 
46 (75) 
15 (25) 
0.730 
CD45R0+ margin density 
(186) 
 
Low 
High 
 
38 (52) 
35 (48) 
 
27 (51) 
26 (49) 
 
31 (52) 
29 (48) 
0.960  
33 (47) 
38 (54) 
 
31 (48) 
33 (52) 
 
32 (63) 
19 (37) 
0.089  
32 (48) 
38 (52) 
 
29 (50) 
29 (50) 
 
37 (57) 
26 (43) 
0.282 
CD45R0+ cancer cell 
density (192) 
 
Low 
High 
 
48 (64) 
27 (36) 
 
43 (80) 
11 (20) 
 
44 (70) 
19 (30) 
0.408  
48 (67) 
24 (33) 
 
46 (70) 
20 (30) 
 
41 (76) 
13 (24) 
0.268  
46 (64) 
26 (36) 
 
39 (67) 
19 (33) 
 
50 (81) 
12 (19) 
0.037 
FOXP3+ margin density 
(186) 
 
Low 
High 
 
37 (51) 
36 (49) 
 
29 (56) 
23 (44) 
 
38 (62) 
23 (38) 
0.180  
39 (53) 
34 (47) 
 
34 (54) 
29 (46) 
 
31 (62) 
19 (38) 
0.373  
40 (60) 
27 (40) 
 
32 (54) 
27 (46) 
 
32 (53) 
28 (47) 
0.466 
FOXP3+ cancer cell nest 
density (188) 
 
Low 
High 
 
26 (36) 
47 (64) 
 
26 (49) 
27 (51) 
 
39 (63) 
23 (37) 
0.002  
39 (53) 
34 (47) 
 
25 (39) 
39 (61) 
 
27 (53) 
24 (47) 
0.807  
38 (56) 
30 (44) 
 
26 (44) 
33 (56) 
 
27 (44) 
34 (56) 
0.181 
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Table 3 The relationship between tumour cell STAT3 and pSTAT3 expression and systemic inflammatory responses of patients undergoing elective, 
potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
  Cytoplasmic STAT3 h-score Nuclear STAT3 h-score Nuclear pSTAT3 h-score 
 Low 
(0-20)  
n=76(%) 
Mod 
(21-65)  
n=56(%) 
High 
(66-168) 
n=64(%) 
P Low 
(0-15) 
n=75(%) 
Mod 
(16-30) 
n=66(%) 
High 
(30-130) 
n=55(%) 
P Low 
(5-80) 
n= 72(%) 
Mod 
(81-105) 
n=61(%) 
High 
(106-205) 
n=63(%) 
P 
Modified Glasgow Prognostic Score  
0 
1 
2 
 
53 (70) 
20 (26) 
3 (4) 
 
33 (59) 
18 (32) 
5 (9) 
 
33 (51) 
19 (30) 
12 (19) 
0.004  
46 (61) 
23 (31) 
6 (8) 
 
42 (64) 
20 (30) 
4 (6) 
 
31 (56) 
14 (26) 
10 (18) 
0.244  
44 (61) 
20 (28) 
8 (11) 
 
36 (59) 
17 (28) 
8 (13) 
 
39 (62) 
20 (32) 
4 (6) 
0.651 
Neutrophil count (195)  
≤7.5x109/L 
>7.5x109/L 
 
67 (88) 
9 (12) 
 
47 (85) 
8 (15) 
 
54 (84) 
10 (16) 
0.515  
63 (85) 
11 (15) 
 
60 (91) 
6 (9) 
 
45 (82) 
10 (18) 
0.676  
60 (85) 
11 (16) 
 
52 (85) 
9 (15) 
 
56 (89) 
7 (11) 
0.470 
Lymphocyte count (195)  
>4x109/L 
≤4x109/L 
 
76 (100) 
0 (0) 
 
54 (98) 
1 (2) 
 
64 (100) 
0 (0) 
0.942  
74 (100) 
0 (0) 
 
66 (100) 
0 (0) 
 
54 (98) 
1 (2) 
0.174   
71 (100) 
0 (0) 
 
61 (100) 
0 (0) 
 
62 (98) 
1 (2) 
0.209 
Platelet count (176)  
≤400x109/L 
>400x109/L 
 
58 (87) 
9 (13) 
 
44 (86) 
7 (14) 
 
48 (83) 
10 (17) 
0.557  
55 (85) 
10 (15) 
 
49 (83) 
10 (17) 
 
46 (88) 
6 (12) 
0.587  
57 (85) 
10 (15) 
 
44 (85) 
8 (15) 
 
49 (86) 
8 (14) 
0.895 
Neutrophil:lymphocyte ratio (195)  
≤5 
>5 
 
62 (82) 
14 (18) 
 
45 (82) 
10 (18) 
 
48 (75) 
16 (25) 
0.350  
61 (82) 
13 (18) 
 
55 (83) 
11 (17) 
 
39 (71) 
16 (29) 
0.131  
56 (79) 
15 (21) 
 
45 (74) 
16 (26) 
 
54 (86) 
9 (14) 
0.352 
Neutrophil:platelet score (176)  
0 
1 
2 
 
52 (78) 
13 (19) 
2 (3) 
 
40 (78) 
7 (14) 
5 (8) 
 
40 (69) 
17 (29) 
1 (2) 
0.441  
47 (72) 
16 (25) 
2 (3) 
 
46 (78) 
10 (17) 
3 (5) 
 
39 (75) 
11 (21) 
2 (4) 
0.831  
49 (73) 
15 (22) 
3 (5) 
 
39 (75) 
11 (21) 
2 (4) 
 
44 (77) 
11 (19) 
2 (4) 
0.602 
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Table 4 Relationship between tumour cell STAT3 and pSTAT3 expression and cancer-specific 
survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
 
 
 N 5-year 
CSS % 
(SE)  
Univariate HR 
(95% CI) 
P Multivariate 
HR (95% CI) 
P 
Cytoplasmic STAT3 
Low-mod expression 
High expression 
 
132 
64 
 
81 (3) 
67 (6) 
 
- 
1.62 (0.96-2.65) 
0.072  
- 
- 
- 
Nuclear STAT3 
Low-mod expression 
High expression 
 
141 
55 
 
78 (4) 
70 (6) 
 
- 
1.89 (1.12-3.22) 
0.018  
- 
- 
- 
Nuclear pSTAT3 
Low-mod expression 
High expression 
 
133 
63 
 
80 (4) 
69 (6) 
 
- 
1.52 (0.90-2.57) 
0.119  
- 
- 
- 
Combined cytoplasmic STAT3/ 
nuclear STAT3 (Model 1) 
Both low-mod 
One high 
Both high 
 
 
106 
61 
29 
 
 
81 (4) 
73 (6) 
63 (9) 
 
 
 
1.56 (1.20-2.17) 
 
0.009  
 
 
- 
0.221 
Combined cytoplasmic STAT3/ 
nuclear pSTAT3 (Model 2) 
Both low-mod 
One high 
Both high 
 
 
95 
75 
26 
 
 
80 (4) 
79 (5) 
54 (10) 
 
 
 
1.50 (1.06-2.13) 
0.024  
 
 
- 
0.526 
Combined nuclear STAT3/ 
nuclear pSTAT3 (Model 3) 
Both low-mod 
One high 
Both high 
 
 
100 
74 
22 
 
 
81 (4) 
74 (5) 
62 (11) 
 
 
 
1.63 (1.14-2.34) 
0.008  
 
 
1.63 (1.14-2.34) 
0.008 
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Table 5 Relationship between combined tumour cell nuclear STAT3/ pSTAT3 expression, clinicopathological characteristics and cancer-specific 
survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
  
Cancer-specific survival 
Clinicopathological characteristics Univariate analysis P Multivariate 
analysis 
P 
Age (<65/ 65-74/ >75) 1.00 (0.73-1.37) 0.986 - - 
Sex (Female/ male) 1.43 (0.84-2.44) 0.188 - - 
Adjuvant therapy (No/ yes) 1.43 (0.83-2.47) 0.196 - - 
Tumour site (Colon/ rectum) 0.99 (0.57-1.74) 0.983 - - 
TNM stage (I /II /III) 2.16 (1.35-3.48) 0.001 - 0.416 
Tumour differentiation (Mod-well/ poor) 1.18 (0.51-2.75) 0.700 - - 
Venous invasion (No/ yes) 3.35 (1.97-5.70) <0.001 2.89 (1.59-5.28) 0.001 
Margin involvement (No/ yes) 2.82 (1.12-7.09) 0.028 - 0.612 
Peritoneal involvement (No/ yes) 2.45 (1.45-4.13) 0.001 - 0.650 
Tumour perforation (No/ yes) 4.34 (1.04-18.11) 0.044 8.30 (1.84-37.43) 0.006 
Modified Glasgow Prognostic Score (0/ 1/ 2) 1.43 (0.99-2.08) 0.057 1.52 (0.98-2.35) 0.060 
NPS (0/ 1/ 2) 1.72 (1.13-2.62) 0.012 1.69 (1.07-2.67) 0.025 
NLR (<5/ >5) 1.13 (0.60-2.13) 0.715 - - 
Mismatch repair status (Competent/ deficient) 1.37 (0.69-2.71) 0.370 - - 
Klintrup-Makinen grade (High/ low) 2.33 (1.20-4.49) 0.012 2.14 (0.97-4.71) 0.060 
Tumour stroma percentage (Low/ high) 2.52 (1.48-4.30) 0.001 - 0.180 
Tumour budding (Low/ high) 3.92 (2.25-6.85) <0.001 4.12 (2.20-7.71) <0.001 
Nuclear STAT3/ nuclear pSTAT3 (Both low-mod/ one high/ both 
high) 
1.63 (1.14-2.34) 0.008 1.28 (0.86-1.89) 0.220 
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Figure 1 The relationship between tumour cell STAT3 expression and cancer-specific 
survival of patients undergoing elective, potentially curative resection of stage I-III colorectal 
cancer (Kaplan-Meier log-rank analysis): (a) cytoplasmic STAT3 expression (P=0.068), (b) 
nuclear STAT3 expression (P=0.012), (c) nuclear pSTAT3 expression (P=0.116), and (d) 
combined nuclear STAT3/pSTAT3 expression (P=0.012) 
 
Supplementary Figure 1 The relationship between tumour cell STAT3 expression and 
cancer-specific survival of patients undergoing elective, potentially curative resection of 
stage I-III colorectal cancer (Kaplan-Meier log-rank analysis): (a) Stage T1-2 (P<0.001), (b) 
Stage T3-4 (P=0.192), (c) Node negative (P=0.516), and (d) Node positive (P=0.001). 
 
